CNS（中枢神経系）治療薬の市場規模、シェア、成長分析：疾患別、薬剤クラス別、流通チャネル別、地域別 - 産業予測 2025～2032年

CNS（中枢神経系）治療薬2023年の市場規模は1,363億7,000万米ドルで、2024年の1,449億6,000万米ドルから2032年には2,363億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.3%で推移する見通しです。

世界の中枢神経系（CNS）治療薬市場は急速に発展しており、治療の拡大を通じてさまざまな神経疾患や精神疾患に対応しています。メンタルヘルスの問題に対する意識の高まりと高齢化によって、この分野は大きな成長を遂げています。継続的な研究開発努力によって治療アプローチが強化される一方、製薬企業と研究機関の戦略的提携がイノベーションを促進しています。技術の進歩が進むにつれ、中枢神経系治療薬市場は多くの人々の生活の質を向上させる態勢を整えています。しかし、規制状況、価格圧力、競合情勢といった課題もあり、複雑な業界情勢をうまく乗り切るには、利害関係者の戦略的対応が必要です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

CNS（中枢神経系）治療薬市場規模：疾患別& CAGR（2025-2032）

• 市場概要
• 神経血管疾患
• 中枢神経系外傷
• メンタルヘルス
  • 不安障害
  • てんかん
  • 気分障害
  • 精神病性障害
  • その他
• 神経変性疾患
  • アルツハイマー病
• パーキンソン病
  • 多発性硬化症
  • ハンチントン病
• 筋萎縮性側索硬化症
  • その他
• 感染症
• 中枢神経系がん
• その他

CNS（中枢神経系）治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 麻酔薬
• 抗けいれん薬
• 制吐剤
• 中枢神経刺激薬
• 鎮痛剤
• その他

CNS（中枢神経系）治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• その他

CNS（中枢神経系）治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Biogen（United States）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Takeda Pharmaceutical Company Limited（Japan）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Johnson & Johnson Services, Inc.（United States）
• Pfizer Inc.（United States）
• Sanofi S.A.（France）
• H. Lundbeck A/S（Denmark）
• UCB S.A.（Belgium）
• PTC Therapeutics（United States）
• Jazz Pharmaceuticals plc（Ireland）
• Acadia Pharmaceuticals, Inc.（United States）
• Neumora Therapeutics（United States）
• Immunic Therapeutics（United States）
• Muna Therapeutics（Denmark）
• NRG Therapeutics（United Kingdom）

結論と提言

CNS (Central Nervous System) Therapeutics Market size was valued at USD 136.37 billion in 2023 and is poised to grow from USD 144.96 billion in 2024 to USD 236.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The Global Central Nervous System (CNS) Therapeutics market is rapidly evolving, addressing a variety of neurological and psychiatric disorders through an expanding array of treatments. Driven by increased awareness of mental health issues and an aging population, this sector is experiencing significant growth. Ongoing research and development efforts are enhancing therapeutic approaches, while strategic collaborations between pharmaceutical firms and research institutions are fostering innovation. As technological advancements continue, the CNS therapeutics market is poised to improve the quality of life for many individuals. However, challenges such as regulatory hurdles, pricing pressures, and intense competition necessitate strategic responses from industry stakeholders to navigate the complex landscape successfully.

Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

CNS (Central Nervous System) Therapeutics Market Segments Analysis

Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the CNS (Central Nervous System) Therapeutics Market

The global aging population is a key driver for the Central Nervous System (CNS) therapeutics market, as an increase in age correlates with a higher incidence of neurological disorders such as Alzheimer's and Parkinson's disease. This demographic transformation creates a substantial demand for effective CNS treatments and therapies, given that elderly individuals face a greater risk of developing these debilitating conditions. Consequently, the growing prevalence of age-related neurological disorders underscores the urgent need for innovative CNS therapeutics, prompting advancements in research and development to address the healthcare challenges associated with this rising population segment.

Restraints in the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) Therapeutics market faces significant restraints primarily due to the complex nature of developing drugs and treatments for neurological and psychiatric disorders. The process necessitates extensive clinical trials and encounters multiple regulatory challenges, resulting in considerable scrutiny from authorities. This rigorous oversight can cause substantial delays in the approval process and escalate costs associated with bringing new therapies to market. Consequently, these barriers hinder not only innovation within the field but also restrict timely access for patients seeking effective treatments, ultimately impacting the overall progress and availability of CNS therapeutics.

Market Trends of the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genetics and neuroimaging technologies. This trend enables healthcare providers to tailor treatments to individual patients based on their unique genetic profiles and neurobiological characteristics, resulting in more precise and effective interventions. By focusing on personalized approaches, the market aims to improve treatment outcomes for prevalent CNS disorders such as Alzheimer's, depression, and schizophrenia while reducing adverse effects associated with traditional therapies. As this paradigm evolves, it holds the potential to transform the landscape of CNS therapeutics, enhancing patient care and efficacy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
• Parkinsosn's Disease
  • Multiple Sclerosis
  • Huntington's Disease
• Amytrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anesthetics
• Anticonvulsants
• Antiemetics
• CNS Stimulants
• Pain Relievers
• Others

Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global CNS (Central Nervous System) Therapeutics Market Size & CAGR (2025-2032)

• North America (Disease, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neumora Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunic Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Muna Therapeutics (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NRG Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations